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ABSTRACT
Objectives: To determine the therapeutic equivalence
and safety of once daily (OD) versus three times daily
(TID) dosing of a total daily dose of 3 g Salofalk
(mesalazine) granules in patients with active ulcerative
colitis.
Design: A randomised, double-blind, double-dummy,
parallel group, multicentre, international, phase III non-
inferiority study.
Setting: 54 centres in 13 countries.
Patients: 380 patients with confirmed diagnosis of
established or first attack of ulcerative colitis (clinical
activity index (CAI).4 and endoscopic index >4a t
baseline) were randomised and treated.
Interventions: 8-week treatment with either 3 g OD or
1 g TID mesalazine granules.
Main outcome measures: Clinical remission (CAI(4)
at study end.
Results: 380 patients were evaluable for efficacy and
safety by intention-to-treat (ITT); 345 for per protocol (PP)
analysis. In the ITT population, 79.1% in the OD group
(n=191) and 75.7% in the TID group (n=189) achieved
clinical remission (p,0.0001 for non-inferiority).
Significantly more patients with proctosigmoiditis
achieved clinical remission in the OD group (86%; n=97)
versus the TID group (73%; n=100; p=0.0298). About
70% of patients in both treatment groups achieved
endoscopic remission, and 35% in the OD group and 41%
in the TID group achieved histological remission. About
80% of all patients preferred OD dosing. Similar numbers
of adverse events occurred in 55 patients (28.8%) in the
OD group and in 61 patients (32.3%) in the TID group,
indicating that the two dosing regimens were equally safe
and well tolerated.
Conclusions: OD 3 g mesalazine granules are as
effective and safe as a TID 1 g schedule. With respect to
the best possible adherence of patients to the treatment,
OD dosing of mesalazine should be the preferred
application mode in active ulcerative colitis.
ClinicalTrials.gov Identifier: NCT00449722
Aminosalicylates (mesalazine, sulfasalazine, olsala-
zine, balsalazide) have been the mainstay of
inflammatory bowel disease treatment for over
60 years.
1 These drugs are prescribed for active
disease as well as for relapse prevention in both
ulcerative colitis and in Crohn’s disease.
Aminosalicylates are the undisputed ‘‘gold stan-
dard’’ for maintaining remission in ulcerative
colitis.
2–4 Furthermore, they may have chemopre-
ventive properties against colorectal cancer.
5
Conventionally, a multiple daily dosing regimen
of aminosalicylates is established. This is a
demanding drug regimen, which can interfere with
the everyday life of a patient, and can therefore
reduce the quality of life. Moreover, the inconve-
nience of this dosing regimen can have a negative
impact on adherence to the drugs, and thus, can
lead to a poorer long-term prognosis. Adherence
rates in prospective, community-based studies
range from 40 to 60%,
67and are particularly poor
among patients in remission.
8–11 Three times per
day (TID) dosing of mesalazine was the most
significant risk factor for partial non-compliance. A
total of 57% of patients who were prescribed
mesalazine TID admitted non-compliance.
10
Moreover, it was shown that non-compliant
patients had a 5-fold risk of experiencing a relapse
as compared to patients taking more than 80% of
their prescribed mesalazine medication.
12 Thus,
patients’ ideal therapy would be an effective, oral
formulation with fewer tablets, less-frequent dos-
ing, and minimal side effects.
13
The dosing regimen of a therapeutic compound
is usually based on its pharmacokinetic and
pharmacodynamic properties such as systemic
bioavailability as well as tissue peak and steady-
state concentrations. However, aminosalicylates
are thought to exert their therapeutic action
topically from the luminal side of the intestines
irrespective of their presence within the systemic
circulation.
14 To this end it may be possible to
modify the dosing regimen to one more acceptable
to the patient, particularly regarding compliance,
and still maintain the therapeutic effect. In
particular, this could involve decreasing the dosing
frequency, and it has been observed that reducing
dosing frequency improves compliance.
15
Mesalazine, the therapeutically active moiety of
sulfasalazine,
16 17 is routinely used in the treatment
of ulcerative colitis. Salofalk granules are a multi-
particulate formulation of mesalazine. Due to their
enteric, acid-resistant film coating the dissolution
starts approximately at pH>6.0, leading to a
delayed and, due to the inner polymer matrix,
prolonged release of the active ingredient through-
out the entire colon.
18 Salofalk granules are easy to
swallow, are preferred by patients compared to
enteric-coated tablets,
19 20 and 1 g TID has been
proven to be the optimal dose for treatment of
acute episodes of ulcerative colitis.
19 The study
aimed to prove that once daily (OD) dosing is at
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of remission in patients with active ulcerative colitis.
MATERIAL AND METHODS
Study population
Men and women aged 18–75 years with a histologically and
endoscopically confirmed diagnosis of established or first attack
of ulcerative colitis (clinical activity index (CAI).4 and
endoscopic index (EI)>4 at baseline, both according to
Rachmilewitz
21), and having an extent of disease .15 cm from
the anus were entered in the study. Major exclusion criteria
were Crohn’s disease, renal or liver insufficiency, baseline stool
positive for bacteria causing bowel disease, immunosuppres-
sants within 3 months and/or corticosteroids within 1 month
prior to baseline, and current relapse that had occurred under
maintenance treatment with .2 g/day mesalazine. All oral or
rectal treatments for ulcerative colitis were to be stopped at
baseline. All study participants gave their written informed
consent prior to inclusion.
Study design
This study was a randomised, double-blind, double-dummy,
parallel group, multicentre clinical trial to evaluate the effect of
dosing frequency of orally administered Salofalk granules (3 g
OD vs 1 g TID) on the efficacy, safety and tolerability in
patients with active ulcerative colitis. The study was performed
according to a sequential adaptive design, with the first interim
analysis planned to be performed after 200 intention-to-treat
(ITT) evaluable patients had finished the trial. The planned
total sample size was 320 patients. The study was conducted at
54 centres in 13 countries: Croatia, Czech Republic, Estonia,
Germany, Hungary, Israel, Latvia, Lithuania, Poland, Russia,
Slovak Republic, Slovenia and Ukraine. Patients were assigned
to the treatment groups 1:1 based on a computer-generated
randomisation scheme. The study treatment lasted 8 weeks,
with control visits at 2, 4 and 6 weeks. Patients were enrolled
from July 2005 to April 2006. A sponsor-independent data
monitoring committee reviewed unblinded data of the interim
analysis.
Objectives
The primary aim of this study was to prove the clinical non-
inferiority of an OD dosing as compared to a conventional TID
dosing for the induction of remission in patients with active
ulcerative colitis. The secondary objective was to compare the
safety and tolerability between the different dosing schedules.
Experimental procedures
Visits were scheduled for days 0 (baseline), 14, 28, 42 and 56
(week 8, final visit). If patients discontinued the study
prematurely, a full final visit was performed if possible. At
baseline, patients were examined physically and their demo-
graphics and medical history were recorded. Vital signs,
laboratory tests, including haematology, biochemistry and
urinalysis, and clinical signs of ulcerative colitis were assessed
at each visit. Baseline and final visits comprised, in addition,
endoscopy and histology. In patients with an established
diagnosis of ulcerative colitis, endoscopy was required at least
up to the proximal margin of inflammation. In newly diagnosed
patients, total colonoscopy was mandatory.
Study medication
Salofalk (mesalazine, 5-aminosalicylic acid (5-ASA)) and
placebo granules were manufactured by Dr Falk Pharma,
Freiburg, Germany. To keep the study double-blinded, a
double-dummy design was used, ie, patients in the OD group
Figure 1 Patient disposition. One
patient was excluded from the intention-
to-treat population because he did not
receive study medication. Patients were
excluded from the per-protocol population
because of protocol deviations.
AEs,adverseevents;ITT, intention-to-treat;
OD, once daily; PP, per protocol;
SAE, serious adverse event;
TID, three times daily.
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placebo both at noon and in the evening; whereas patients in
the TID group had to administer 1 g mesalazine in the morning,
at noon and in the evening and, additionally, 2 g placebo in the
morning.
Concomitant medications involved in the treatment of
ulcerative colitis were not allowed during the study, including
steroids, antibiotics, immunosuppressants, non-steroidal anti-
inflammatory drugs, other forms of aminosalicylates, lopera-
mide, psyllium-containing drugs, or new onset of probiotics.
OUTCOME MEASURES
Primary efficacy variable
The primary endpoint was the percentage of patients achieving
clinical remission defined as a CAI(4 at the end of the study
(with the ‘‘last observation carried forward’’ (LOCF) approach)
in each of the two groups. The well-established CAI was
calculated as the sum of the scores of seven variables (number of
weekly stools, bloody stools, abdominal pain, general well-
being, body temperature, extra-intestinal manifestations, ery-
throcyte sedimentation rate/haemoglobin).
21 The scores for the
first four variables were based on data collected in the patient’s
diary during the 7 days preceding a study visit. Patients had to
complete a daily diary throughout the study, which comprised
seven items: number of stools, number of bloody stools, degree
of rectal bleeding, general well-being, abdominal pain, regular
intake of the study medication, and concomitant therapy
administered. Disease was classified as mild if baseline CAI
was (8 and moderate if CAI.8.
Secondary efficacy variables
Clinical improvement was defined as a decrease in CAI by at
least 1 point from baseline to the individual study end.
Additional endpoint was the disease activity index (DAI),
22
with a modification of the mucosal subscore according to the
US Food and Drug Administration (FDA) recommendation, ie,
mucosal friability moved from a score of 1 to a score of 2,
23 and
active disease was defined as a bleeding score of .0 and mucosal
appearance score of >2 at baseline, and remission defined as a
bleeding score of 0 and mucosal appearance score of (1. The
endoscopic index (EI) was evaluated according to
Rachmilewitz,
21 with endoscopic remission defined as EI,4.
Table 1 Patient baseline characteristics (intention-to-treat)
Mesalazine, 3 g once daily
(n=191)
Mesalazine, 1 g three times daily
(n=189) p Value
Male, n (%) 94 (49.2) 96 (50.8) 0.7582{
Mean (SD) age, years 41.8 (14.0) 43.3 (13.8) 0.2896{
Mean body mass index (SD) 24.8 (4.6) 25.0 (4.3) 0.7599{
Caucasian, n (%) 189 (99.0) 189 (100.0) 0.1584{
Smoking status, n (%) 0.9781{
Current smoker 18 (9.4) 19 (10.1)
Non-smoker 133 (69.6) 131 (69.3)
Former smoker 40 (20.9) 39 (20.6)
Diagnosis, n (%) 0.8618{
New diagnosis 50 (26.2) 48 (25.4)
Established disease 141 (73.8) 141 (74.6)
Median time since diagnosis, years (range) 2.8 (0.1–36.5) 3.1 (0.0–34.2) 0.39151
Course of the established disease, n (%) 0.5552{
Chronically active disease 5 (3.5) (n=141) 7 (5.0) (n=141)
Relapsing disease 136 (96.5) (n=141) 134 (95.0) (n=141)
Mean number of previous episodes/relapses (relapsing disease) (SD) 4.3 (5.2) (n=135) 5.1 (5.2) (n=132) 0.2004{
Median duration of present acute episode (relapsing disease), days (range) 27.0 (2–428) (n=136) 29.5 (2–275) (n=134) 0.53851
Disease localisation, n (%) 0.1703{
Distal disease 97 (50.8%) 100 (52.9%)
Proctosigmoiditis
Proximal disease 94 (49.2%) 89 (47.1%)
Left-sided colitis 55 (28.8%) 40 (21.2%)
Subtotal-/pancolitis 39 (20.4%) 49 (25.9%)
Mean length of inflammation, cm (SD) 49.1 (27.5) (n=176) 49.5 (25.3) (n=177) 0.8948{
Mean disease activity (SD)
Clinical activity index 8.1 (2.2) 7.9 (2.2) 0.5593{
Modified disease activity index 7.4 (1.7) 7.0 (1.7) 0.0356{
Endoscopic index 7.5 (1.9) 7.4 (1.9) 0.5149{
Disease severity, n (%) 0.5697{
Mild (CAI(8) 121 (63.4) 125 (66.1)
Moderate (CAI.8) 70 (36.6) 64 (33.9)
Pre-study maintenance medication*, n (%) 94 (69.1) (n=136) 89 (66.4) (n=134) 0.6351{
Oral 5-aminosalicylate 59 (43.4) 53 (39.6)
Oral sulfasalazine 26 (19.1) 26 (19.4)
Rectal 5-aminosalicylate 10 (7.4) 9 (6.7)
Immunosuppressants 3 (2.2) 1 (0.7)
Oral corticosteroids 2 (1.5) 1 (0.7)
Disease activity index with modified mucosal subscore (mucosal friability moved from a score of 1 to a score of 2).
*Doses of the pre-study medication did not violate the exclusion criterion. {x
2 test, two-sided. {t test, two-sided. 1Wilcoxon rank-sum test, t approximation, two-sided.
CAI, clinical activity index; SD, standard deviation.
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DAImucosal>2, mucosal healing at the final endoscopy was
defined as a modified DAImucosal(1. Biopsies were taken from
at least the sigmoid and the rectum and investigated by a
central pathologist who was also blinded to the treatment
given. The histological index (HI) was determined according to
Riley et al
24; the total HI was based on the most severely
inflamed segment. Time to first resolution of clinical symptoms
was defined as the time from baseline to the day when the
patient recorded for the first time in his or her diary to have no
more than three bowel movements, all without blood. The
physician’s global assessment (PGA) was evaluated on a 6-point
scale according to Hanauer et al.
6
Safety variables
The frequency of adverse events (AEs) and clinically relevant
changes in laboratory parameters (including a renal safety
assessment) and vital signs were assessed. Compliance with
study medication was checked by counting the medication
returned at the follow-up visits.
Sample size and statistical methods
For proving therapeutic equivalence (non-inferiority) of OD vs
TID treatment, a one-sided test hypothesis was used. The non-
inferiority margin was predefined as 215% for the difference of
the remission rates between treatments. Assuming remission
rates of 65% under both treatments, a sample size of 160
patients in each treatment arm was calculated to achieve an
80% power to yield a statistical significant result. As the study
was conducted using a three-stage group sequential test
design,
25 26 the boundary p value at the first interim analysis
was given as p1=0.0048; thus the overall type I error rate of
a=0.025 (one-sided) was maintained.
27 For confirmative proof
of non-inferiority, the rate of clinical remission was tested using
a x
2 test with maximum likelihood estimation according to
Farrington and Manning,
28 and differences between the remis-
sion rates and corresponding 97.5% one-sided repeated con-
fidence intervals (CIs) were provided.
29 The confirmatory test
was based on the per-protocol (PP) analysis set. In addition, a
sensitivity analysis was performed in the ITT population (ie, all
randomised patients who had received the study medication).
All other group comparisons were of an exploratory nature. For
evaluation of secondary efficacy end points, 95% CIs were
calculated for the differences between the two treatment groups
OD vs TID. The median time to first symptomatic remission, in
days, and the corresponding 95% CI was calculated for each
treatment group using the Kaplan–Meier estimation. Treatment
groups were compared by calculating the hazard ratio and the
corresponding 95% CI assuming proportional hazards.
RESULTS
Patient characteristics
A total of 381 patients with ulcerative colitis (191 for the OD
group, 190 for the TID group) were enrolled (fig 1). One patient,
randomised to the TID group, did not receive study medication
and, thus, was excluded from all analyses sets.
A total of 347 (91%) patients completed the study at the 8-
week endpoint (fig 1). The main reasons for discontinuation of
the treatment in these 33 patients were: lack of efficacy (6/17,
3% OD group; 7/16, 4% TID group); protocol violation (6/17,
3% OD group; 3/16, 2% TID group); adverse event (1/17, 0.5%
TID group, baseline histology sample showed signs of amyloi-
dosis); and other reasons (3% in each group).
There were no statistically significant differences between the
treatment groups regarding the demographic and baseline
disease characteristics, or pre-study maintenance medication
(see table 1). Approximately three-quarters of the patients had
established disease; half of the patients had distal ulcerative
colitis, and two-thirds had mild disease. Only two-thirds of the
patients with relapsing disease received maintenance medica-
tion for ulcerative colitis prior to enrolment, therefore oral
mesalazine and sulfasalazine in mean dosages corresponding to
less than or equal to 2 g mesalazine/day were the most common
treatments. There were no differences between patients
receiving maintenance treatment or not with regard to the
distribution of their disease localisation.
Clinical effects
Primary efficacy endpoint
In the ITT population, 151/191 patients (79.1%) in the OD
group and 143/189 patients (75.7%) in the TID group achieved
clinical remission. Therefore, non-inferiority between the OD
and TID group was concluded with a highly significant p value
(p,0.0001) and a very tight 95% CI for the difference between
both treatment groups (3.4% (25.0% to 11.8%)). The results for
the PP population were completely in line with those observed
in the ITT population and confirmed the therapeutic equiva-
lence between both treatment schedules (fig 2).
Influence of covariates on primary efficacy endpoint
The predefined exploratory subgroup analyses of the primary
endpoint are presented for the ITT population in table 2.
Evaluation clinical remission rates with regard to gender or
disease duration ((5 years vs .5 years) did not show any
statistically significant differences between and within each of
the groups. With respect to baseline severity, there was no
difference in the remission rates between the OD and TID
group. However, within the OD group significantly more
patients with mild as compared to moderate disease achieved
clinical remission (85% vs 69%; p=0.0067; x
2 test, two-sided).
Disease localisation also had an impact on the remission rates
Figure 2 Clinical remission rates (CAI(4) at week 8 (LOCF). x
2 test
(one-sided) for proving non-inferiority of OD vs TID treatment, with a pre-
defined non-inferiority margin of 215% for the difference of the
remission rates between treatments. CAI, clinical activity index;
CI, confidence interval; ITT, intention-to-treat; LOCF, last observation
carried forward; OD, once daily; PP, per protocol; TID, three times daily.
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(ie, left-sided, subtotal, pancolitis) was observed between the
OD and TID groups, there was a significant difference in distal
disease between the groups (86% vs 73%; p=0.0298; x
2 test,
two-sided) as well as within the OD group itself between distal
and proximal disease (86% vs 72%; p=0.0247; x
2 test, two-
sided). Previous maintenance treatment with up to 2 g
mesalazine had no impact on the outcome compared to patients
who did not receive maintenance therapy (OD 78% vs 81%,
p=0.6649; TID 72% vs 80%, p=0.3094; x
2 test, two-sided).
Secondary efficacy endpoints
All secondary efficacy endpoints were in line with the primary
endpoint and supported the conclusion of therapeutic equiva-
lence between the OD and TID groups. The results of the ITT
population presented below were almost identical to those
observed in the PP population.
Clinical activity index
In addition to clinical remission, approximately a further 13–
15% of the patients experienced clinical improvement with no
difference between groups (ITT). Clinically relevant sub-scores,
ie, number of stools and number of bloody stools improved
equally well in both groups; 107/191 (56%) and 109/189 (58%)
of the patients in the OD and TID groups, respectively, had
complete normal stool frequency, and 125/191 (65%) and 125/
189 (66%) had no bloody stool at the end of the study. The time
course of the CAI over the study period, as shown in fig 3, as
well as the mean (SD) change from baseline in the CAI (OD,
25.5 (3.1); TID, 25.2 (3.4); p=0.4360, t test) did not reveal any
differences between the groups.
Time to first resolution of symptoms
The median time to first resolution of symptoms (ie, (3 stools/
day and free of blood) was 12 and 16 days in the OD and TID
group, respectively (ITT). The hazard ratio of 0.961 together
with a 95% CI of 0.771 to 1.197 indicated no clinically
significant differences between the groups.
Modified disease activity index
As a secondary efficacy endpoint, the modified DAI score was
used. Remission, defined according to the FDA recommendation
as a bleeding score of 0 and mucosal appearance score of (1,
was obtained in 128/191 patients (67%) in the OD group and
122/187 patients (65.2%) in the TID group, respectively (ITT),
with a difference in the proportion (95% CI) between the OD
and TID groups of 1.8% (27.8% to 11.3%).
Endoscopy and histology
Endoscopic remission using the EI was obtained in 135/191
patients (71%) in the OD group and 132/189 (70%) in the TID
group at the end of the study (ITT). For patients with a baseline
modified DAImucosal>2, mucosal healing was obtained in 136/
182 patients (75%) in the OD group and 129/177 (73%) in the
TID group at the end of the study (ITT), with a difference in
the proportion (95% CI) between the OD and TID groups of
1.8% (27.3% to 10.9%). There was no significant difference
between these values, and no significant difference in EI was
observed between the two groups for the course of the study.
Histological remission was observed in 67/191 patients (35%)
in the OD group and 77/189 patients (41%) in the TID group.
Improvement was observed in another 46 patients (24%) in the
OD group and 33 (17%) in the TID group. There was no
statistically significant difference between the groups.
Physician’s global assessment
Therapeutic success, ie, at least a marked improvement in
symptoms as rated by the PGA, was observed in 145/191
patients (76%) in the OD group and in 140/189 (74%) in the
TID group. Therapeutic benefit of treatment, ie, at least slight
improvement of symptoms, was observed in 176/191 patients
(92%) in the OD group and 168/189 (89%) in the TID group.
There were no differences between the groups.
Dosing preference of the study medication
Patients were asked which kind of dosing schedule they would
prefer. The vast majority of all patients 313/380 (82%) preferred
Table 2 Clinical remission rates (CAI) by baseline covariates (intention-to-treat)
Number (%) of patients in clinical
remission (CAI(4) at final visit (LOCF)
Mesalazine 3 g OD
(n=191)
Mesalazine 1 g TID
(n=189)
Difference (%)
OD 2 TID (95% CI)
p Value, x
2
(two-sided)
Gender
Male 76/94 (81%) 76/96 (79%) 1.6 (29.7 to 13.1) 0.7717
Female 75/97 (77%) 67/93 (72%) 5.3 (27.1 to 17.6) 0.4027
Disease duration
(5 years 95/121 (79%) 87/116 (75%) 3.5 (27.2 to 14.3) 0.5220
.5 years 56/70 (80%) 56/73 (77%) 3.3 (210.2 to 16.8) 0.6334
Severity (CAI at baseline)
(8 points (mild disease) 103/121 (85%)* 99/125 (79%) 5.9 (23.6 to 15.5) 0.2255
.8 points (moderate disease) 48/70 (69%) 44/64 (69%) 20.2 (215.9 to 15.5) 0.9822
Disease location
Distal disease 83/97 (86%){ 73/100 (73%) 12.6 (1.4 to 23.7) 0.0298
Proximal disease 68/94 (72%) 70/89 (79%) 26.3 (218.7 to 6.1) 0.3217
Distal disease: proctosigmoiditis.
Proximal disease: left-sided ulcerative colitis/subtotal-/pancolitis.
*The difference (95%) in remission (mild vs moderate) within the OD group was 16.6% (4.0 to 29.1) (p=0.0067).
{The difference (95%) in remission (proctosigmoiditis vs left-sided/pancolitis) within the OD group was 13.2% (1.8 to 24.7)
(p=0.0247).
CAI, clinical activity index; CI, confidence interval; LOCF, last observation carried forward; OD, once daily; TID, three times daily.
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TID schedule, and 55/380 (14%) had no preference. For 6/380
patients (2%) no data were available.
Safety and tolerability
A total of 78 treatment-emergent adverse events (TEAEs)
occurred in 55/191 patients (29%) taking 3 g mesalazine OD
and 83 TEAEs occurred in 61/189 patients (32%) taking 1 g
mesalazine TID. The most common TEAEs were headache,
worsening of ulcerative colitis, and nasopharyngitis (table 3). A
causal relationship with study drug was considered as at least
possible for eight TEAEs in 6/191 patients, (3%) in the OD
group and for 10 TEAEs in 9/189 patients (5%) in the TID
group. The vast majority of patients with adverse events
experienced TEAEs of mild (OD, 43/55 patients (78%); TID, 47/
61 patients (77%)), or moderate intensity (OD, 14/55 patients
(25%); TID, 16/61 patients (26%)). Adverse events of severe
intensity occurred only in seven patients of the OD group and
in three patients of the TID group (most often ‘‘colitis
aggravated’’). In total, seven serious adverse events (SAEs)
occurred in six patients (OD, four patients; TID, two patients).
None of these SAEs was related to the study drug. No deaths
occurred during this study. Nine AEs occurring in seven patients
of the OD group, and seven AEs in seven patients of the TID
group led to withdrawal of the study drug, with ‘‘deterioration
of ulcerative colitis’’ as the most frequent reason for withdrawal
(five patients in each group).
Overall, no clinically relevant trends were observed in the
course of the laboratory parameters. Urinary function tests
using sensitive early markers of renal disease (a1-microglobulin,
b-N-acetyl-D-glucosaminidase (b-NAG), cystatin C) showed no
impairment of renal function, and indicated that an oral OD
dose of 3 g mesalazine, which is associated with higher peak-
plasma levels as compared to a 1 g TID regimen, is at least as
safe as a 1 g TID dose with regard to potential tubulo-toxicity.
On the contrary, decreases in these parameters even indicate an
improvement of tubular function.
DISCUSSION
The aim of the present study was to compare the efficacy
and safety of two dosing regimens of the mesalazine
preparation Salofalk granules in inducing remission in mild
to moderate active ulcerative colitis. The total daily dose of
3 g was either given once a day (OD) or in divided portions
three times per day (TID).
Both dosing regimens showed similar therapeutic effects,
with 79% and 76% of the patients in the OD and TID groups,
respectively, achieving clinical remission (ITT), which confirms
the efficacy of mesalazine granules for the treatment of
ulcerative colitis observed in previous randomised controlled
trials.
19 20 The fact that very similar results were observed in the
PP and ITT populations, and that the lower boundaries of the
95% CI for the difference between OD and TID were 23.5%
(PP) and 25.0% (ITT), indicated that the conclusion of non-
inferiority of 3 g OD vs 1 g TID is based on robust data.
Moreover, it is of interest that nearly all values, although not
statistically significantly different, favoured the OD dosing.
So far, only two other confirmative phase III studies have
investigated the therapeutic efficacy of OD dosing of mesalazine
in active ulcerative colitis,
30 31 and were recently summarised in
a combined analysis.
23 In order to compare the efficacy results
between these studies and the current one, we used the same
definition for remission in a post-hoc analysis as was used in
these MMX mesalazine trials,
23 ie, total modified DAI score (1,
with scores of zero for rectal bleeding and stool frequency, a
combined PGA and sigmoidoscopy score of 1 or less, no
friability, and at least a 1-point reduction from baseline in the
sigmoidoscopy score. Using this very stringent definition, 70/
191 patients (37%) in the OD group and 73/189 (39%) in the
TID Salofalk granules group achieved remission (ITT popula-
tion). These rates were nearly identical to those reported in the
pooled analysis for 2.4 g/day (64/172 (37%)) and 4.8 g/day
MMX mesalazine (61/174 (35%)), respectively.
There were no differences between the OD and TID groups
with regard to influence of the remission rates by the duration
of ulcerative colitis and baseline disease severity, although
patients with mild ulcerative colitis showed better remission
rates than those with moderate disease. Of interest is the
significantly greater therapeutic effect of the OD dosing in
proctosigmoiditis patients. Consequently, it may be hypothe-
sised that OD dosing leads to higher luminal peak concentra-
tions, particularly in the distal colon and that an OD dosing of
mesalamine granules is well suited for oral treatment of distal
disease, and thus might also enhance a patient’s compliance to
treatment, as most of the patients prefer the oral over the rectal
route of administration.
Figure 3 Course of the mean clinical activity index during the study
(ITT). CAI, clinical activity index; ITT, intention-to-treat; LOCF, last
observation carried forward; OD, once daily; SD, standard deviation;
TID, three times daily.
Table 3 Treatment-emergent adverse events
3 g mesalazine OD
(n=191)
1 g mesalazine TID
(n=189)
Any TEAE 55 (28.8) 61 (32.3)
Any potential treatment-related AE 6 (3.1) 9 (4.8)
AE that led to withdrawal 7 (3.7) 7 (3.7)
Most frequent TEAEs occurring in more
than 3% of patients
Headache 9 (4.7) 15 (7.9)
Deterioration of ulcerative colitis 8 (4.2) 10 (5.3)
Nasopharyngitis 6 (3.1) 8 (4.2)
Any SAE 4 (2.1) 2 (1.1)
Individual SAEs
Ulcerative colitis 4 (2.1)* 1 (0.5)
Viral upper respiratory tract infection 1 (0.5)* 0
Measles 0 1 (0.5)
Results are given as the number (%) of patients experiencing at least one treatment-
emergent adverse event (TEAE).
*One patient in the OD group experienced both SAEs.
AE, adverse event; OD, once daily; SAE, serious adverse event; TID, three times daily.
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differences between the two dosing regimens. Mucosal healing
rates, defined as modified DAImucosal(1 at week 8 (LOCF), were
in both mesalazine granules OD and TID groups (75% and 73%,
respectively) comparable to those observed under treatment
with 2.4 g/day (58/84 patients (69%)) and 4.8 g/day (66/85
patients (78%)) MMX mesalazine,
30 and thus, again pointed
towards similar therapeutic efficacy between both formula-
tions.
Here, as in many other studies of mesalazine, treatment with
the study medication was well tolerated and there was no
difference in the occurrence of adverse events between the two
dosing regimens. The majority of adverse events were mild or
moderate in intensity and no unexpected side effects occurred,
including no adverse effects on renal function, which had
detailed observation throughout the study. The safety profile of
the OD dosing is supported by the findings from a pharmaco-
kinetic trial which showed that there is no accumulation of
mesalazine during the steady-state dosing with 3 g OD
mesalazine granules (arithmetic mean (SD) of accumulation
ratios of the area under the curve was 1.17 (0.45), and at the
maximal concentration time point it was 1.14 (0.39)).
32
Intervention on dosing frequency affects both adherence and
clinical outcome.
33 Motivation to follow the treatment schedule
can be increased by more suitable drug formulations and user-
friendly intake frequencies. Indeed, in this study the vast
majority of patients preferred a once-daily treatment schedule,
and a content of 1.5 g mesalazine granules per sachet made it
easy to take a total dose of 3 g per day. Non-adherence to the
regimen of a prescribed medication is still a major and critical
problem affecting the efficacy of a treatment, especially for
long-term maintenance treatment. Kane showed that non-
compliant patients had a 5-fold risk of relapses compared to
patients taking more than 80% of their prescribed mesalazine
medication.
12 Moreover, Shale and Riley
10 reported that
approximately only half of patients adhere to the prescribed
dosing schedule especially under a divided dosing regimen (three
times daily), resulting in a median amount of medication
administered of approximately 70% of the dose.
In conclusion, a 3 g once-daily dose of mesalazine granules
(Salofalk granules) is at least as effective as a divided dose of 1 g
given three times daily, and brings a substantial proportion of
patients with mild-to-moderate active ulcerative colitis into
clinical and endoscopic remission. Mesalazine granules demon-
strated an excellent safety profile, independently of the mode of
dosing. With respect to the best possible adherence of the
patients to the treatment, once daily dosing of mesalazine
should be the preferred mode of application in active ulcerative
colitis.
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The following were investigators in the International Salofalk OD Study Group.
Croatia: Mate Kozic, Ivo Klarin, Zvonimir Matas, Domagoj Kasun, Jadranko Turcinov,
Roko Marcelic: Zadar.
Czech Republic: Bohumil Fixa, Tomas Vanasek: Hradec Kralove; Libor Gabalec, Vladimir
Simon: Usti nad Orlici; Pavel Kohout: Prague; Jan Kykal: Ricany; Tomas Vich: Hranice.
Estonia: Karin Kull, Riina Salupere, Hele Remmel, Peeter Koiva, Katrin Labotkin: Tartu.
Germany: Wojtek Baniewicz, Susanne Bonnet, Bernd Vohmann: Mannheim; Wolfgang
Kruis, Stephan Bo ¨hm: Cologne; Thomas Zeisler: Halle; Ju ¨rgen Zeus: Erlangen.
Hungary: Ja ´nos Banai, Tama ´s Szamosi, Zso ´fia Czegle ´di: Budapest; Pa ´l Demeter,
Ro ´bert Sike, Jo ´zsef Penyige, Levente Ba ´lint, Krisztina Sa ´rdi, Ferenc Huora ´nszki:
Budapest; Zoltan Do ¨bro ¨nte, Lilla Lakner, Zsolt Jakab: Szombathely; La ´szlo ´ Lakatos,
Ga ´bor Mester, Csolnoky Ferenc: Veszpre ´m; Istva ´n Ra ´cz, Andrea Szabo ´, Gyula Pe ´csi,
Miha ´ly Cso ¨ndes, Hussam Saleh, Tibor Ka ´ra ´sz: Gyo ¨r; Zsolt Tulassay, La ´szlo ´ Hersze ´nyi,
Anna Ma ´ria Ne ´meth, Pa ´l Miheller: Budapest; La ´szlo ´U ´jsza ´szy, Andor Grenda: Miskolc;
Borbala Velo ¨sy, Zsolt Vira ´nyi, Zsolt Dubravcsik: Kecskeme ´t.
Israel: Simon Bar-Meir, Moshe Nadler: Tel Hashomer; Iris Dotan, Guy Rosner, Roman
Grenshpon: Tel Aviv; Rami Eliakim, Irit Chermesh: Haifa; Mark Faszczyk, Arkady
Berezovsky, Genadi Katz: Ashkelon; Dan Keret, Victoria Mindrul: Jerusalem; Alexandra
Lavy, Dean Keren: Haifa; Ehud Melzer, Yuval Binder: Rechovot; Yaron Niv, Gerald
Martin Fraser, Ebrahim Zebeede, Eyal Gal: Petach Tikva.
Latvia: Jelena Derova, Aleksejs Derovs: Riga; Juris Pokrotnieks, Aldis Pukitis, Mairita
Ergle: Riga.
Lithuania: Gitana Acute, Violeta Vainoriute, Vytautas Metrikis, Algimantas Cepulis:
Siauliai; Kestutis Adamonis, Arlandas Modzeliauskas: Kaunas; Audrone Buineviciute,
Narimantas Samalavicius, Gintautas Radziunas: Vilnius; Gediminas Kiudelis, Limas
Kupcinskas, Laimas Jonaitis: Kaunas; Giedrius Simulionis, Saulius Petrauskas, Valdas
Kuolas: Klaipeda; Raimonda Vanagaitiene, Antanas Jablonskis, Ausra Navikiene:
Vilnius.
Poland: Marek Horynski, Dariusz Kleczkowski: Sopot; Adam Kopon, Ewa Kopon:
Torun; Krzysztof Marlicz, Halina Jaroszewicz-Heigelmann, Izabela Binkowska, Michal
Wasilewicz: Szczecin; Aleksander Sieron, Wojciech Latos, Witold Zieleznik, Karolina
Sieron-Stoltny: Bytom; Leszek Szczepanski, Robert Zwolak, Dariusz Chudzik, Mariusz
Piotrowski, Marcin Mazurek: Lublin; Antoni Wysokinski, Romuald Grodzienski,
Wojciech Kosikowski, Jaroslaw Drabko, Agnieszka Forys: Lublin.
Russia: Igor G. Bakulin, Vladislav G. Novozhenov, Marina A. Ivanova, Vladimir M.
Ruseikin, Kerimulah D. Malabaev: Moscow; Elena A. Belousova, Tamara S.
Mishurovskaya, Inna V. Nikulina: Moscow; Aleksander I. Gorelov, Elena A. Sishkova,
Dmitry V. Raspereza, Tatiana V. Tinyakova: Saint-Petersburg; Vladimir B. Grinevich,
Irina V. Gubonina, Anatoly M. Pershko: Saint-Petersburg; Tatyana L. Mikhailova, Oleg
V. Golovenko, Ludmila A. Mayat, Pavel A. Makarchuk, Natalya S. Malakhova: Moscow;
Emilia P. Yakovenko, Andrey V. Yakovenko, Natalya A. Agafonova, Antonina S.
Pryanishnikova, Aleksandr N. Ivanov: Moscow; Konstantin P. Zhidkov, Oleg N. Bulavin,
Fuza D. Albegova, Maria V. Vasilukova: Saint-Petersburg.
Slovak Republic: Boris Baricky ´: Nitra; Marian Ba ´tovsky ´: Bratislava; Bozena
Peka ´rkova ´, Boris Pekarek: Trnava.
Slovenia: Milan Stefanovic, Zdravko Tosovic, Ljiljana Ljepovic: Bled.
Ukraine: Andrey Dorofeyev, Kira Lynevskaya, Olga Rassokhina: Donetsk; Yurii
Silvestrovich Lozynsky, Maria Lozynska, Stanislav Golovchansky: Lvov; Mikhail
Petrovich Zakharash, Yurii Zakharash, Tetyana Kravchenko: Kiev.
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